目的 探讨采用癫痫康胶囊联合奥卡西平治疗癫痫的临床疗效。方法 选取荆州市第一人民医院2015年5月-2017年5月收治的癫痫患者163例，随机分成对照组（81例）和治疗组（82例）。对照组患者口服奥卡西平片，起始剂量150 mg/d，然后加量1次/2周，最大量600 mg/d维持治疗，2次/d；治疗组患者在对照组的基础上口服癫痫康胶囊，3粒/次，3次/d。两组患者均治疗3个月。观察两组患者临床疗效，同时比较治疗前后两组患者同型半胱氨酸（Hcy）水平、平均症状控制时间和癫痫发作次数及精神状态和日常生活能力评分。结果 治疗后，对照组和治疗组临床有效率分别为83.95%和95.12%，两组比较差异具有统计学意义（P<0.05）。治疗后，两组患者Hcy水平较治疗前显著升高（P<0.05），两组平均症状控制时间和癫痫发作次数显著减少（P<0.05），且治疗后治疗组平均症状控制时间和癫痫发作次数明显少于对照组（P<0.05）。治疗后，两组患者精神状态评分显著升高（P<0.05），日常生活能力评分显著降低（P<0.05），且治疗组患者两项评分明显优于对照组（P<0.05）。结论 癫痫康胶囊联合奥卡西平治疗癫痫患者疗效显著，不良反应发生率低，具有一定的临床推广应用价值。

Objective To investigate the clinical efficacy of Dianxiankang Capsules combined with oxcarbazepine in treatment of epilepsy. Methods Patients (163 cases) with epilepsy in Jingzhou First people's Hospital from May 2015 to May 2017 were randomly divided into control (81 cases) and treatment (82 cases) groups. Patients in the control group were po administered with Oxcarbazepine Tablets, the initial dosage was 150 mg/d, then increased once every 2 weeks, and the maximum dose was 600 mg/d for maintenance treatment, twice daily. Patients in the treatment group were po administered with Dianxiankang Capsules on the basis of the control group, 3 grains/time, three times daily. Patients in two groups were treated for 3 months. After treatment, the clinical efficacy was evaluated, and the Hcy level, the average time of symptom control and seizure frequency, the mental state and activity of daily living in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control and treatment groups was 83.95% and 95.12% respectively, and there were differences between two groups (P<0.05). After treatment, the Hcy levels in two groups were significantly increased (P<0.05), the average time of symptom control and seizure frequency was significantly decreased (P<0.05), and the average time and frequency in the treatment group after treatment was significantly less than that in the control group (P<0.05). After treatment, the mental state scores in two groups were significantly increased (P<0.05), the activity of daily living scores were significantly decreased (P<0.05), and the two scores in the treatment group after treatment were significantly better than those in the control group (P<0.05). Conclusion Dianxiankang Capsules combined with oxcarbazepine in treatment of epilepsy has significant clinical effect with low adverse reactions incidence, which has a certain clinical application value.